NHS Ambient Voice Technology Market Heats Up in the UK - key players include TORTUS AI, Heidi Health, ClinicLetter.ai, Scribetech, Suki, Nuance, Tandem
- Lloyd Price
- Jun 13
- 8 min read
Updated: Jun 18
NHS Ambient Voice Technology Market Heats Up in the UK - key players include TORTUS AI, Heidi Health, ClinicLetter.ai, Scribetech, Suki, Nuance, Tandem
The NHS ambient voice technology market in the UK is indeed a rapidly evolving and competitive space, driven by the critical need to alleviate administrative burdens on clinicians and improve patient care.
Nelson Advisors delves into the roles of these players and the broader trends:
Key Players and Their Contributions:
TORTUS AI remains a leading player, actively involved in significant NHS trials, notably the London-wide AVT trial led by Great Ormond Street Hospital for Children. Their "Surgery Intellect" solution focuses on generating clinical notes, referral letters, and coding directly from consultations, aiming to reduce administrative time and improve clinician focus on patients. They have demonstrated promising results in reducing admin and are expanding their presence in GP practices, hospitals, and ambulance services. https://tortus.ai
Heidi Health is gaining traction with its AI-powered medical scribe, which transcribes patient visits, generates clinical notes, and drafts documents. They emphasize robust UK compliance, local data hosting, and temporary data storage to ensure data security and privacy, which is crucial for NHS adoption. https://www.heidihealth.com/uk
ClinicLetter.ai fits directly into the ambient voice technology space, focusing on generating medical letters and documentation from clinician-patient conversations. While specific large-scale NHS trial details might be less publicly prominent than some other players, their core offering directly addresses a key administrative pain point in the NHS. ClinicLetter.ai leverages generative AI to convert spoken words into structured medical documentation. https://www.clinicletter.ai
Scribetech continues to be a strong contender with its "Augnito Omni" AI scribe technology and "Augnito Spectra" for speech recognition. Building on their extensive experience in providing transcription services to the NHS, they are well-positioned to integrate advanced AI into existing workflows, aiming for significant reductions in documentation time and seamless Electronic Patient Record (EPR) integration. https://scribetech.co.uk
Suki AI offers an AI assistant that provides ambient documentation, dictation, and coding capabilities, along with the ability to answer clinician questions. Their focus on deep integration with major EHRs and minimizing hallucination risks aligns with NHS requirements for reliable and accurate data. Their partnership with Google Cloud indicates a commitment to leveraging advanced AI platforms. https://www.suki.ai/suki-platform/
As part of Microsoft, Nuance is a powerful force in the market. Their "Dragon Medical One" and "Dragon Copilot" solutions utilize advanced speech recognition and AI to enhance productivity, improve the value of clinical data, and streamline workflows for healthcare professionals. Their long-standing presence and integration capabilities are significant advantages. https://www.microsoft.com/en-gb/health-solutions
Tandem Health, through its partnership with Accurx (a widely used NHS communications platform), is deploying "Accurx Scribe, powered by Tandem." This collaboration allows them to provide real-time transcription, coding, and document generation to a vast network of NHS professionals, directly addressing the need to reduce admin time and enable clinicians to focus on patient interaction. https://www.tandemhealth.ai
Market Dynamics and Trends in the UK NHS:
Growing Adoption and NHS Endorsement
The NHS is actively encouraging and supporting the adoption of ambient voice technologies. NHS England recently published guidance on the use of AI-enabled ambient scribing products, signifying a move towards broader and more structured deployment across primary and secondary care settings. This guidance highlights the transformative potential of these tools.
Key Drivers:
Reducing Administrative Burden and Clinician Burnout: This is arguably the most significant driver. Clinicians spend a substantial amount of time on documentation, leading to burnout and reduced patient face-to-face time. AVT offers a solution to automate much of this, freeing up valuable clinical hours.
Improving Efficiency and Productivity: By streamlining documentation and workflow, AVT can increase the number of patients seen, especially in high-pressure environments like A&E, and improve overall system capacity.
Enhancing Patient Care and Experience: When clinicians are less focused on typing, they can engage more meaningfully with patients, leading to better communication, increased patient satisfaction, and potentially improved health outcomes.
Addressing Data Quality: AVT can contribute to more consistent and accurate data capture, which is vital for better clinical decision-making, population health management, and supporting frontline digitisation goals.
Promising Trial Results: Interim data from trials, such as the London-wide AVT trial at Great Ormond Street Hospital for Children (which involved evaluating capabilities across various settings and over 7,000 patients), has shown positive results in terms of increased direct patient care time and improved productivity.
Challenges and Considerations
Data Privacy and Security: Ensuring compliance with GDPR, the Data Protection Act, and NHS-specific standards (like DCB0129, DTAC, DSPT, Cyber Essentials Plus) is paramount. Solutions must demonstrate robust end-to-end encryption, data minimisation, and local data hosting. NHS England has issued directives warning against the use of non-compliant solutions.
Regulatory Compliance: AVT solutions, especially those using generative AI for summarisation or potential diagnoses, are increasingly being classified as medical devices (MHRA Class 1 or 2a), requiring rigorous registration and compliance.
Accuracy and Hallucinations: While AI is powerful, ensuring the accuracy of generated notes and mitigating the risk of "hallucinations" (AI generating incorrect or fabricated information) is critical for patient safety. Clinician review and validation of all AI-generated outputs remain essential.
Integration with EPRs: Seamless and reliable integration with existing Electronic Patient Record systems (e.g., EMIS, SystmOne, Epic, Cerner) is crucial for the practical utility and widespread adoption of AVT.
Cost and Scalability: While the long-term benefits are clear, the initial cost of deployment and ensuring scalability across the diverse NHS landscape can be a challenge, particularly with budget constraints.
Ethical Concerns and Clinician Acceptance: Concerns about over-reliance on AI, potential erosion of clinical judgment, and the ethical implications of AI interpreting conversations need to be addressed through proper governance, training, and ongoing evaluation.
Future Outlook
The NHS sees AI, including ambient voice technology, as a key component of its digital transformation strategy. Future developments are expected to include even deeper integration with EHRs, more sophisticated clinical decision support, and "true ambient" functionality that operates passively in the background.The NHS Shared Business Services is also developing a new framework agreement for AI solutions in healthcare, which will likely further streamline procurement for these technologies.
The NHS ambient voice technology market is vibrant, with numerous players vying to provide solutions that can truly revolutionise how clinicians work and how patients experience healthcare in the UK. The emphasis remains on responsible innovation, ensuring patient safety, data security and tangible benefits for the overstretched NHS workforce.
NHS funding for Ambient Voice Technology in the UK
NHS funding for Ambient Voice Technology (AVT) in the UK is primarily driven by a strategic imperative to leverage AI to improve efficiency, reduce administrative burden, and ultimately enhance patient care. While there isn't a single, dedicated "AVT fund," funding flows through various channels and initiatives.
Here's a breakdown of how NHS funding supports AVT:
1. Central Government Investment and Initiatives
"Plan for Change" and Digital Transformation: The UK Government has explicitly stated its determination to embrace AI and shift the NHS from "analogue to digital." This broader agenda includes significant investment in innovative technology. The Health and Social Care Secretary, Wes Streeting, has highlighted that the record £26 billion invested in the NHS and social care includes "cash to roll out more pioneering tech."
AI in Health and Care Award: This is a major funding mechanism run by the Accelerated Access Collaborative (AAC) in partnership with the National Institute for Health Research (NIHR) and NHS AI Lab. It makes substantial funding available to accelerate the testing and evaluation of promising AI technologies, including those related to ambient voice. The award supports technologies across various development phases, from initial feasibility to multi-site deployment and real-world evaluation, with uncapped awards for later phases.
AI Diagnostic Fund: While specifically focused on diagnostic tools, this £21 million fund (announced in 2023) demonstrates the government's commitment to deploying AI across hospitals to speed up diagnosis and treatment.While not directly for AVT, it shows a willingness to fund AI solutions that deliver tangible benefits.
NHS England Guidance and National Propositions: NHS England actively guides and encourages the use of AI-enabled ambient scribing products. This guidance often comes with the backing of broader programs designed to deliver a national proposition for rolling out assured, standardised services across England. This national push indicates a commitment to facilitate local adoption.
Trials and Evaluations: NHS England-funded, London-wide AVT work, led by Great Ormond Street Hospital (GOSH), has been a significant example of central funding for trialing and evaluating ambient voice technology across diverse clinical settings. The promising interim data from these trials is crucial for building the evidence base for wider commissioning.
2. Local NHS Trust and Integrated Care Board (ICB) Procurement
Direct Procurement: Individual NHS Trusts and Integrated Care Boards (ICBs) have the autonomy to procure AI solutions, including ambient voice technology, directly from suppliers. This is often driven by local needs and the perceived benefits of the technology in addressing specific challenges, such as reducing administrative burden or improving clinician-patient interaction.
Value for Money: When bidding for funds or directly procuring, NHS organizations are required to demonstrate value for money, ensuring that the investment in AVT will lead to clear benefits that outweigh the costs.
Partnerships with Suppliers: Many AVT providers offer solutions through commercial agreements with individual NHS organisations, sometimes starting with pilot programs or free licenses to demonstrate efficacy before broader adoption.
3. Research and Innovation Funding
NIHR Funding Programmes: Beyond the specific AI in Health and Care Award, the NIHR (National Institute for Health and Care Research) has various funding programmes that support research in AI and data science, some of which may indirectly or directly fund projects involving ambient voice technology if they align with the research priorities (e.g., AI for Multiple Long-Term Conditions, AI and Racial and Ethnic Inequalities).
Academic Health Science Networks (AHSNs) / Health Innovation Networks: These networks play a role in identifying, evaluating, and accelerating the adoption of innovation within the NHS. They may provide support or smaller grants for pilot projects involving AVT.
Key Considerations for Funding and Adoption
Evidence Base: While early results are promising, continued rigorous evaluation and the building of a robust evidence base for the impact of AVT are crucial for securing long-term, widespread funding and adoption.
Scalability and Interoperability: Solutions that can scale across different care settings and integrate seamlessly with existing Electronic Patient Records (EPRs) are more likely to attract sustained investment.
Responsible AI: The emphasis on patient safety, data security, and ethical considerations is paramount. Funding is likely to favour solutions that demonstrate robust adherence to these principles.
Human-in-the-Loop: The current preference for human review and validation of AI-generated outputs ensures that AI acts as an assistant rather than a replacement, influencing how funding is allocated for solutions that support, rather than fully automate, clinical processes.
Addressing Workforce Needs: AVT is viewed as a critical tool to alleviate the administrative burden on the NHS workforce, a major driver for investment given the widespread issues of burnout and staff shortages.
In summary, NHS funding for Ambient Voice Technology is part of a larger national strategy to digitalise and optimise healthcare delivery. It flows through dedicated AI awards, general technology investment, and local procurement decisions, all underpinned by the need for demonstrable benefits, responsible innovation, and a clear return on investment for the overstretched NHS.
Nelson Advisors > Healthcare Technology M&A
.
Nelson Advisors specialise in mergers, acquisitions & partnerships for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies based in the UK, Europe and North America. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Healthcare Technology thought leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
We share our views on the latest Healthcare Technology mergers, acquisitions & partnerships with insights, analysis and predictions in our LinkedIn Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Founders for Founders > We pride ourselves on our DNA as ‘HealthTech entrepreneurs advising HealthTech entrepreneurs.’ Nelson Advisors partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #BuySide #SellSide
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Contact Us
Meet Us
Digital Health Rewired > 18-19th March 2025 > Birmingham, UK
NHS ConfedExpo > 11-12th June 2025 > Manchester, UK
HLTH Europe > 16-19th June 2025, Amsterdam, Netherlands
HIMSS AI in Healthcare > 10-11th July 2025, New York, USA
World Health Summit 2025 > October 12-14th 2025, Berlin, Germany
HLTH USA 2025 > October 18th-22nd 2025, Las Vegas, USA
MEDICA 2025 > November 11-14th 2025, Düsseldorf, Germany
Nelson Advisors > Leading European Healthcare Technology M&A Advisory
Comentarios